S&P Futures
3,920.25-2.25(-0.06%)Dow Futures
31,950.00+34.00(+0.11%)Nasdaq Futures
13,245.25-56.75(-0.43%)
Sunesis Pharmaceuticals, Inc. (SNSS)
Chart Events
Performance Outlook
| Previous Close | 4.28 |
| Open | 4.67 |
| Bid | 0.00 x 1400 |
| Ask | 0.00 x 3200 |
| Day's Range | 4.70 - 7.09 |
| 52 Week Range | 1.12 - 11.10 |
| Volume | 70,241,798 |
| Avg. Volume | 2,024,641 |
| Market Cap | 27.524M |
| Beta (5Y Monthly) | 2.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.79 |
| Earnings Date | Nov 16, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.17 |
Fair Value
Related Research
- PR Newswire
Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc. (previously trading on Nasdaq under "SNSS"). The combined, publicly traded company will focus on the advancement and expansion of Viracta's clinical stage pipeline, including Viracta's lead program for the treatment of Epstein-Barr virus (EBV)-positive lymphoma. Shares of the combined company, which is operating under the name Viracta Therapeutics, Inc., will commence trading on the Nasdaq Global Select Market under the ticker symbol "VIRX" on February 25, 2021.
- Benzinga
Sunesis Pharma Climbs After Viracta Poised To Nab US Patent For Nanatinostat/Valganciclovir Regime
Sunesis Pharmaceuticals Inc (NASDAQ: SNSS) merger partner, Viracta Therapeutics Inc announces that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 16/924,082, titled "Methods of Treating Virally Associated Cancers with Histone Deacetylase Inhibitors," related to the use of Viracta's oral combination product candidate of nanatinostat and valganciclovir. The allowed claims cover the anticipated dose regimen to be advanced in the planned global registration trial to treat Epstein-Barr virus (EBV)-associated lymphoma and other lymphoproliferative disorders. Upon its grant, the resulting patent will provide protection into at least 2040. In November last year, Sunesis Pharmaceuticals announced to merge with Viracta Therapeutics in an all-stock deal. Price Action: SNSS gained 5.5% at $3.49 in market trading hours on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaAddex Therapeutics' GABAB PAM Candidate Shows Potential For Alcohol Use DisorderWindtree Therapeutics' AEROSURF Drug Delivery Device Secures US Patent© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- PR Newswire
Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma
Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 16/924,082. The allowed application, titled "Methods of Treating Virally Associated Cancers with Histone Deacetylase Inhibitors," describes the use of Viracta's all-oral combination product candidate of nanatinostat, the Company's proprietary investigational drug, and valganciclovir. The allowed claims cover the anticipated dose regimen to be advanced in the planned global registration trial for the treatment of Epstein-Barr virus (EBV)-associated lymphoma and other lymphoproliferative disorders. Upon its grant, the resulting patent will provide protection into at least 2040.
